These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38472412)

  • 21. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers.
    Eszlinger M; Stewardson P; McIntyre JB; Box A; Khalil M; Hyrcza M; Koro K; Ruether D; Wu J; Paschke R
    Eur Thyroid J; 2022 Jan; 11(1):. PubMed ID: 34981751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution.
    Macerola E; Proietti A; Poma AM; Ugolini C; Torregrossa L; Vignali P; Basolo A; Materazzi G; Elisei R; Santini F; Basolo F
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature.
    Otsubo R; Mussazhanova Z; Akazawa Y; Sato A; Matsuda K; Matsumoto M; Yano H; Matsuse M; Mitsutake N; Ando T; Niino D; Nagayasu T; Nakashima M
    J Pediatr Endocrinol Metab; 2018 Mar; 31(4):461-467. PubMed ID: 29427554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
    Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
    Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological features of two cases of
    Ke J; Cao M; Zhang W; Huang H; Chen P; Liu J; Shan D; Ke J; Wang Z; Liu J; Li Y; Xiao S
    Front Oncol; 2024; 14():1332522. PubMed ID: 38863624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
    Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
    Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Major Oncogenic Drivers and Their Clinicopathological Correlations in Sporadic Childhood Papillary Thyroid Carcinoma in Belarus.
    Rogounovitch TI; Mankovskaya SV; Fridman MV; Leonova TA; Kondratovitch VA; Konoplya NE; Yamashita S; Mitsutake N; Saenko VA
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational Profile of Papillary Thyroid Carcinoma in an Endemic Goiter Region of North India.
    George N; Agarwal A; Kumari N; Agarwal S; Krisnani N; Gupta SK
    Indian J Endocrinol Metab; 2018; 22(4):505-510. PubMed ID: 30148098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
    Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nodal Metastases Associated With Fusion Oncogenes Are Age Dependent in Young Adult Patients With Thyroid Cancer.
    Li H; Han R; Meng L; Sun Y; Zhao M; Zhou W; Xie J; Yu D; Shen L; Zhou Y; Wang S; Yan J; Wang W; Ye L
    J Clin Endocrinol Metab; 2023 Dec; 109(1):143-150. PubMed ID: 37536280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma.
    Liu Y; Wu S; Zhou L; Guo Y; Zeng X
    J Clin Endocrinol Metab; 2021 Mar; 106(4):1129-1138. PubMed ID: 33382428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
    Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.